Treatment of Inflammatory Immunologic Disease 4. B Cell Targeting Therapy Using the Anti-CD20 Antibody Rituximab in Inflammatory Autoimmune Diseases
Author:
Affiliation:
1. The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan
Publisher
Japanese Society of Internal Medicine
Subject
General Medicine,Internal Medicine
Link
http://www.jstage.jst.go.jp/article/internalmedicine/46/16/46_16_1313/_pdf
Reference5 articles.
1. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
2. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab
3. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
4. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploring the role of immunotherapeutic drugs in autoimmune diseases: A comprehensive review;Journal of Oral Biology and Craniofacial Research;2021-04
2. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus;Rheumatology International;2020-08-14
3. Long-term Successful Treatment of Rituximab for Steroid-resistant Minimal Change Nephrotic Syndrome and Idiopathic Thrombocytopenic Purpura;Internal Medicine;2020-04-01
4. Successful treatment of refractory acute lupus haemophagocytic syndrome using rituximab: a case report;Modern Rheumatology Case Reports;2020-01-06
5. Successful treatment of a patient with refractory immune thrombocytopenic purpura in systemic lupus erythematosus with rituximab;Immunological Medicine;2019-10-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3